CEFOTAXIME Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefotaxime, and what generic alternatives are available?
Cefotaxime is a drug marketed by Fresenius Kabi Usa, Hikma, Wockhardt, B Braun, Aurobindo Pharma, Aurobindo Pharma Ltd, Cephazone Pharma, Hospira, Hospira Inc, and Lupin. and is included in fourteen NDAs.
The generic ingredient in CEFOTAXIME is cefotaxime sodium. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cefotaxime sodium profile page.
Summary for CEFOTAXIME
US Patents: | 0 |
Applicants: | 10 |
NDAs: | 14 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 37 |
Patent Applications: | 5,608 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEFOTAXIME at DailyMed |
Recent Clinical Trials for CEFOTAXIME
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Assiut University | Phase 4 |
Cairo University | Phase 4 |
Dr. Promise Tamunoipiriala Jaja | Phase 2 |
Pharmacology for CEFOTAXIME
Drug Class | Cephalosporin Antibacterial |